Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

ABSTRACT:

Unlabelled

Recurrent CNS lymphoma continues to be associated with poor outcomes in the rituximab era. Although IV rituximab mediates superior disease control of systemic non-Hodgkin lymphoma (NHL), it fails to completely eliminate the risk of meningeal recurrence, likely due to minimal CNS penetration. Given that rituximab acts synergistically with chemotherapy, we conducted the first phase 1 study of intraventricular immunochemotherapy in patients with recurrent CNS NHL. Fourteen patients received 10 mg or 25 mg intraventricular rituximab twice weekly for 4 weeks, with rituximab administered as monotherapy during the first treatment each week and rituximab administered in combination with methotrexate (MTX) during the second treatment each week. More than 150 doses were administer

SUBMITTER: Rubenstein JL 

PROVIDER: S-EPMC3563362 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature